下降:在HER2阳性,雌激素受体阴性,结节阴性早期乳腺癌中缓解化疗
Véronique Debien1, Virginie Adam2, Elisabeth Coart3
1Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Brussels, Belgium.
本研究评估了一种针对HER2阳性,HR阴性早期乳腺癌的新型HER2向疗法,旨在减少有毒化疗. DECRESCENDO试验的重点是通过优化治疗策略来实现无复发性生存.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 乳腺癌研究研究 乳腺癌研究
背景情况:
- 丰富HER2的亚型在HER2阳性,激素受体阴性乳腺癌中很常见.
- 人环素化疗具有严重的毒性,促使需要优化HER2向治疗.
- 乳腺癌的早期治疗旨在改善生存率,并最大限度地减少长期副作用.
研究的目的:
- 评估新辅助药物珀图祖马布和特拉斯图祖马布组合在HER2阳性,HR阴性早期乳腺癌中的疗效和安全性.
- 评估HER2丰富瘤患者实现病理完整反应的3年无复发生存率.
- 探索基于新辅助疗法反应的适应辅助治疗策略.
主要方法:
- DECRESCENDO试验 (NCT04675827):一个大型的,多中心的,单臂的II期研究.
- 新辅助剂皮下注射珀图祖马布和特拉斯图祖马布固剂组合加上基于税的化疗.
- 辅助治疗根据反应进行调整;灵活的护理副研究,用于门诊治疗.
主要成果:
- 主要终点:HER2丰富瘤患者的3年无复发生存期和病理完整响应.
- 评估治疗反应以指导随后的辅助治疗决策.
- 评估门诊辅助治疗的可行性.
结论:
- 优化HER2向治疗可能允许在特定的乳腺癌亚型中省略有毒的环素.
- DECRESCENDO试验研究了一种针对HER2阳性,HR阴性早期乳腺癌的新型治疗方法.
- 进一步的数据将确定该策略的长期无复发生存和安全概况.
更多相关视频
10:13Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment
Published on: June 21, 2022
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
